The cost-effectiveness of medical versus surgical androgen deprivation therapy for advanced prostate cancer in Tanzania: a Markov model-based analysis. [PDF]
Nyongole O +9 more
europepmc +1 more source
Natural Product‐Induced Ferroptosis to Overcome Therapy Resistance in Aggressive Cancers
Natural products trigger ferroptosis through iron overload, glutathione depletion, glutathione peroxidase 4 inhibition, and reactive oxygen species accumulation, selectively targeting aggressive, and drug‐resistant cancers. Polyphenols, alkaloids and terpenoids emerge as promising multi‐target agents to overcome therapy resistance and improve future ...
Giorgio Antoniolli
wiley +1 more source
Shared decision-making in prostate cancer treatment: selecting an androgen deprivation therapy option. [PDF]
Collins SP, Maculaitis MC, Chakoian M.
europepmc +1 more source
Letter to the Editor on "Effects of Surgical and Medical Androgen Deprivation on Bladder Remodeling and Steroid Receptor Expression: An Experimental Rat Study". [PDF]
Lin KJ, Lin PT, Lin YH.
europepmc +1 more source
Effects of Surgical and Medical Androgen Deprivation on Bladder Remodeling and Steroid Receptor Expression: An Experimental Rat Study. [PDF]
Yenmez MK, Sevinç C, Güler Y.
europepmc +1 more source
Salvage Metastasis-Directed Therapy Without Androgen Deprivation for Positron Emission Tomography-Defined Oligorecurrent Prostate Cancer: Results of the SOAR Phase II Trial. [PDF]
Crockett E +22 more
europepmc +1 more source
Tailored Personas of Online Health Information-Seeking Behaviors Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy: Qualitative Study. [PDF]
Hou S +6 more
europepmc +1 more source
Response to the Letter to the Editor Regarding "Effects of Surgical and Medical Androgen Deprivation on Bladder Remodeling and Steroid Receptor Expression: An Experimental Rat Study". [PDF]
Yenmez MK, Sevinç C, Güler Y.
europepmc +1 more source
Longitudinal [<sup>18</sup>F]FDG PET/MR Assessment of Arterial Inflammation in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy. [PDF]
Xue S +10 more
europepmc +1 more source
Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer. [PDF]
Azad AA +9 more
europepmc +1 more source

